Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has successfully completed a global private placement, raising A$260 million to fund the US commercial launch of its product Ryoncil for pediatric SR-aGvHD. The capital will also support clinical development, manufacturing expansion, and general corporate purposes. This strategic move is expected to enhance Mesoblast’s operational capabilities and market positioning, particularly in the US, while also signaling strong shareholder support for its innovative cellular therapies.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines aimed at treating severe inflammatory conditions. The company employs a proprietary mesenchymal lineage cell therapy technology platform to create therapies that address severe inflammation by modulating immune system responses. Mesoblast’s Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease (SR-aGvHD), and the company is also focused on developing therapies for other inflammatory diseases and conditions.
YTD Price Performance: -25.68%
Average Trading Volume: 101,786
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.98B
Learn more about MSB stock on TipRanks’ Stock Analysis page.
